Fast Forward has a vision – a world free of multiple sclerosis – a vision you undoubtedly share.
More than 2 million people around the world live with MS, and every hour of every day, someone else is diagnosed with this chronic and unpredictable disease. Millions of dollars are invested annually in critical research, and have led to the six FDA-approved drugs in existence today. These drugs may slow the progression of the disease for some, but for others, these drugs do nothing at all. People with MS need more treatment options now.
Fast Forward acts as a catalyst, connecting people, ideas, and vital resources to accelerate the development of new treatments for people with MS. We bridge the gap between groundbreaking research knowledge, and the commercial resources necessary to move those discoveries into the drug development process. Bringing treatments to people with MS - Faster.
Fast Forward News:
- Fast Forward Funds Development of New Symptom Treatment for Multiple Sclerosis
- Fast Forward, LLC and Five Prime Therapeutics, Inc. Collaborate on Development of Innovative Biological Molecule to Speed New Treatments to People with Multiple Sclerosis
- Cognosci Inc. of Research Triangle Park receives funding support through Fast Forward
- BioBusiness for the Week Ended January 22 - BioCentury Part II
- MS, Diabetes Groups Form Partnership With Italian Biotech In Drug-Discovery Effort
- Fast Forward in MS - Science — Business eXchange
- Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes
- Small Biotechs Increasingly Seek Funds From Nonprofit Groups
- MS Society Teams with Merck KGaA on $19M R&D Pact
- Merck Collaboration to Fast Forward MS Drug Development
